Latham & Watkins Advises Immuneering in Series B Financing

The US$62 million financing was led by a Boston-based emerging companies team.

January 06, 2021

Immuneering Corporation has announced the completion of an oversubscribed US$62 million Series B financing led by Cormorant Asset Management, with participation from Surveyor Capital (a Citadel company), Rock Springs Capital, funds and accounts advised by T. Rowe Price Associates, Inc., funds and accounts managed by BlackRock, Perceptive Advisors and LYFE Capital. Existing investors and senior management also participated in the financing.

Latham & Watkins LLP represents Immuneering Corporation in the transaction with an emerging companies deal team led by Boston partners John Chory and Evan Smith, with associates Andres Caicedo and Martha Anderson.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.